Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/wegovy/wisconsin/madison
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Madison, WI

Verified Wegovy providers in Madison, WI. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
38
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Wisconsin
38 of 38 shown

Find an Wegovy provider in Wisconsin.

Every entry is checked against the NPI registry and the Wisconsin medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Wisconsin city · /wegovy/wisconsin/{city}
Milwaukee
31 →
Green Bay
31 →
§ 03Getting Wegovy in Madison
38 providers · Madison, WI

How to get Wegovy in Madison.

38 GLP-1 prescribers and 7 local resource types are on record for Madison, plus 2 nearby towns in the directory.

Prescribers in Madison
38 prescribers
38 GLP-1 prescribers in Madison, most listed as Family Medicine (15), Internal Medicine, Endocrinology, Diabetes & Metabolism (14) and Internal Medicine (8). Any Wisconsin-licensed physician, nurse practitioner, or PA can prescribe Wegovy, over video or in person. The nearest towns on record are Milwaukee (31 providers) and Green Bay (31 providers).
Around the prescription in Madison
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Madison.
Medicaid (weight loss)
Covered
As of April 2026, Wisconsin Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Wisconsin’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Wisconsin

Diagnosed diabetes reaches 9.6% of adults in Wisconsin.

of Wisconsin adults have obesity
37.4%
diagnosed diabetes
9.6%

Age-adjusted estimates for Wisconsin, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Wegovy in Madison
6 dietitians

The prescription is one part. Here is the rest, in Madison.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Madison, WI, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Danielle Alexander, RDN
RD
Registered dietitian
600 Highland Ave
Call 608-263-9416NPI 1275140055
Corinne Altamira, MS, RD, LDN
RD
Registered dietitian
1102 S Park St
Call 608-263-7500NPI 1235696642
Erika Anna, RDN, CD
RD
Registered dietitian
400 S Townline Rd
Call 920-787-5514NPI 1215662978
Janice Antoniewicz-Werner, CD
RD
Registered dietitian
1313 Fish Hatchery Rd
Call 608-252-8000NPI 1790741288
Lesley Appleyard, R.D., C.D
RD
Registered dietitian
600 Highland Ave
Call 608-890-5500NPI 1801127683
Erin Ard, MS, RDN, CD
RD
Registered dietitian
1675 Highland Ave
Call 608-263-7337NPI 1396435475

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tanya Hansen, RN BSN
NUTRITIONIST
Nutritionist · Education
20 S Park St
Call 608-287-2770NPI 1598732679
Marian Holton-Manuel, Nutritionist
NUTRITIONIST
Nutritionist
6401 Dylyn Dr
Call 608-335-4496NPI 1578294096
Apiramy Jeevananthan, RD
NUTRITIONIST
Nutritionist
2202 S Park St
Call 608-443-5480NPI 1548980840
Jill Lamers
NUTRITIONIST
Nutritionist · Education
4849 Sheboygan Ave Apt 111
Call 608-658-2976NPI 1609573260
Michelle Pagoaga, RN
NUTRITIONIST
Nutritionist · Education
20 S Park St
Call 608-287-2770NPI 1851352215
Deborah Roussos, RD
NUTRITIONIST
Nutritionist
1265 John Q Hammons Dr
Call 608-251-4156NPI 1720171549
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in Wisconsin

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in Wisconsin
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in Wisconsin
Clinics running GLP-1 programs, telehealth & in-person.
Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Wegovy in Alabama→Wegovy in Alaska→Wegovy in Arizona→Wegovy in Arkansas→Wegovy in California→Wegovy in Colorado→Wegovy in Connecticut→Wegovy in Delaware→Wegovy in Florida→Wegovy in Georgia→Wegovy in Hawaii→Wegovy in Idaho→Wegovy in Illinois→Wegovy in Indiana→Wegovy in Iowa→Wegovy in Kansas→Wegovy in Kentucky→Wegovy in Louisiana→Wegovy in Maine→Wegovy in Maryland→Wegovy in Massachusetts→Wegovy in Michigan→Wegovy in Minnesota→Wegovy in Mississippi→Wegovy in Missouri→Wegovy in Montana→Wegovy in Nebraska→Wegovy in Nevada→Wegovy in New Hampshire→Wegovy in New Jersey→Wegovy in New Mexico→Wegovy in New York→Wegovy in North Carolina→Wegovy in North Dakota→Wegovy in Ohio→Wegovy in Oklahoma→Wegovy in Oregon→Wegovy in Pennsylvania→Wegovy in Rhode Island→Wegovy in South Carolina→Wegovy in South Dakota→Wegovy in Tennessee→Wegovy in Texas→Wegovy in Utah→Wegovy in Vermont→Wegovy in Virginia→Wegovy in Washington→Wegovy in West Virginia→Wegovy in Wisconsin→Wegovy in Wyoming→
Related GLP-1 research
plateaus on Wegovy and Ozempic
The plateau playbook: dose, habits, and what the trials say.
§ 09Frequently asked: Wegovy in Wisconsin

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]